# Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella

> **NCT03148990** · PHASE2,PHASE3 · COMPLETED · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 432 (actual)

## Conditions studied

- Rubella
- Measles

## Interventions

- **BIOLOGICAL:** Measles and Rubella vaccine
- **BIOLOGICAL:** Measles, Mumps and Rubella vaccine

## Key facts

- **NCT ID:** NCT03148990
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-20
- **Primary completion:** 2020-08-12
- **Final completion:** 2020-08-12
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2020-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03148990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03148990, "Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03148990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*